You are here

  • Home
  • Archive
  • Volume 20, Issue Suppl 1
  • TCH-052 Validation of an Automated Method For Compounding Monoclonal Antibody Patient Doses: Case Studies of Bevacizumab, Infliximab and Trastuzumab.

Alerts

Article menu

Download PDFPDF

Technology (including: robots for production, incompatibilities, drug production and analytics, CRS)
TCH-052 Validation of an Automated Method For Compounding Monoclonal Antibody Patient Doses: Case Studies of Bevacizumab, Infliximab and Trastuzumab.
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address